PARIS – Global law firm Reed Smith advised Claret Capital Partners and BlackRock Growth in connection with a financing of up to €130 million for Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company developing oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), a chronic and progressive liver disease.

The financing, structured in committed tranches, includes a €43 million contribution from Claret Capital Partners, alongside funds and accounts managed by BlackRock, for a total of up to €130 million, as well as an additional uncommitted tranche of up to €20 million. It forms part of Inventiva’s comprehensive capital structure optimisation, ahead of the anticipated top-line Phase 3 readout in the fourth quarter of 2026, and extends the company’s cash runway into early 2028.

Based in London, Claret Capital Partners is Europe’s largest independent growth debt fund manager. Its team has a track record of over 25 years in financing the innovative technology and life sciences sectors, supporting management teams and their venture capital partners in financing their growth.

Claret Capital Partners and BlackRock Growth were advised by a Reed Smith team comprising Guilain Hippolyte, partner, and Marco Hazan, associate, as well as Ilana Smadja, partner, and Erij Akremi, associate, on the financing aspects.

About Reed Smith

Reed Smith is a dynamic international law firm dedicated to helping clients move their businesses forward. With an inclusive culture and innovative mindset, we deliver smarter, more creative legal services that drive better outcomes for our clients. Our deep industry knowledge, long-standing relationships and collaborative structure make us the go-to partner for complex disputes, transactions, and regulatory matters.

Related news

Related Insights